• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>NeuroImage: Clinical >Chronic exposure to dopamine agonists affects the integrity of striatal D 2 receptors in Parkinson's patients
【24h】

Chronic exposure to dopamine agonists affects the integrity of striatal D 2 receptors in Parkinson's patients

机译：长期暴露于多巴胺激动剂会影响帕金森氏病患者纹状体D 2 受体的完整性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We aimed to investigate the integrity and clinical relevance of striatal dopamine receptor type-2 (D 2 R) availability in Parkinson's disease (PD) patients. We studied 68 PD patients, spanning from early to advanced disease stages, and 12 healthy controls. All participants received one [ 11 C]raclopride PET scan in an OFF medication condition for quantification of striatal D 2 R availability in vivo . Parametric images of [ 11 C]raclopride non-displaceable binding potential were generated from the dynamic [ 11 C]raclopride scans using implementation of the simplified reference tissue model with cerebellum as the reference tissue. PET data were interrogated for correlations with clinical data related to disease burden and dopaminergic treatment. PD patients showed a mean 16.7% decrease in caudate D 2 R and a mean 3.5% increase in putaminal D 2 R availability compared to healthy controls. Lower caudate [ 11 C]raclopride BP ND correlated with longer PD duration. PD patients on dopamine agonist treatment had 9.2% reduced D 2 R availability in the caudate and 12.8% in the putamen compared to PD patients who never received treatment with dopamine agonists. Higher amounts of lifetime dopamine agonist therapy correlated with reduced D 2 Rs availability in both caudate and putamen. No associations between striatal D 2 R availability and levodopa treatment and dyskinesias were found. In advancing PD the caudate and putamen D 2 R availability are differentially affected. Chronic exposure to treatment with dopamine agonists, but no levodopa, suppresses striatal D 2 R availability, which may have relevance to output signaling to frontal lobes and the occurrence of executive deficits, but not dyskinesias. Highlights ? D 2 R in caudate and putamen are differentially affected in PD. ? Loss of D 2 R in caudate correlates with longer disease duration. ? Dopamine agonists treatment, but not levodopa, suppresses caudate and putamen D 2 Rs. ? No association between striatal D 2 R availability, levodopa treatment and dyskinesia.
机译：我们旨在调查帕金森病（PD）患者纹状体多巴胺2型受体（D 2 R）可用性的完整性和临床相关性。我们研究了68例PD患者，从早期到晚期疾病阶段，以及12名健康对照者。所有参与者均在非药物治疗条件下接受了一次[11 C]雷氯必利PET扫描，以量化体内纹状体D 2 R的利用率。使用简化的参考组织模型（以小脑作为参考组织）的实施，通过动态[11 C] raclopride扫描生成[11 C] raclopride不可移位结合势的参数图像。询问PET数据是否与与疾病负担和多巴胺能治疗有关的临床数据相关。与健康对照组相比，PD患者的尾状D 2 R平均减少16.7％，而肠D 2 R可用性平均增加3.5％。尾状[11 C]雷氯必利BP ND较低与PD持续时间较长有关。与从未接受过多巴胺受体激动剂治疗的PD患者相比，接受多巴胺受体激动剂治疗的PD患者的尾状D 2 R利用率降低了9.2％，壳聚糖降低了12.8％。终生多巴胺激动剂治疗量的增加与尾状核和壳状核中的D 2 Rs利用率降低相关。没有发现纹状体D 2 R的可用性与左旋多巴治疗和运动障碍之间的关联。在提高PD时，尾状和壳状D 2 R的可用性受到不同的影响。长期暴露于多巴胺受体激动剂的治疗中，但没有左旋多巴，会抑制纹状体D 2 R的可用性，这可能与额叶的输出信号和执行缺陷的发生有关，但与运动障碍无关。强调 ？尾状和壳状核中的D 2 R在PD中受到不同的影响。 ？尾状D 2 R的丧失与更长的疾病持续时间有关。 ？多巴胺激动剂治疗可抑制尾状和壳核D 2 Rs，但不抑制左旋多巴。 ？纹状体D 2 R的可用性，左旋多巴治疗和运动障碍之间没有关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号